Julio-Septiembre 2003 N°16
ISSN 1317-987X
 
Buscar




Artículos
 
Consideraciones generales
Evaluación inicial del paciente con neutropenia febril
Terapia antibiótica empírica
Recomendaciones para tratamiento de pacientes neutropénicos febriles
Infecciones fúngicas y virales
Medidas adicionales
Referencias




Infectología
Neutropenia Febril: una revisión del tema

Referencias

  1. Torres HA, Bodey GP, Rolston KVI, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in Patients with Aplastic Anemia: Experience at a Tertiary Care Cancer Center. Cancer 2003 Jul 1;98(1):86-93.
  2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 Mar 15;34(6):730-51.
  3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64(2):328-340.
  4. Pizzo, PA. Fever in Immunocompromised Patients. N Engl J Med. 1999;341(12): 893-900.
  5. Pizzo PA. The compromised host. In: Goldman L, Bennett JC, eds. Cecil textbook of medicine. 21st ed. Philadelphia: W.B. Saunders, 2000:1569-1581.
  6. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
  7. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975;135:715-9.
  8. Kinnunen U, Syrjala H, Koskela M, Kujala P, Koistinen P. Continuous-monitoring blood culture screening system improves the detection of bacteremia in neutropenic patients. Scan J Infect Dis 1996;28:287-92.
  9. Mackowiak PA, Bartlett JG, Borden EC, et al. Concepts of fever: recent advances and lingering dogma. Clin Infect Dis 1997;35:119-38.
  10. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis. 2002 Aug;15(4):377-82.
  11. De Pauw B. Infections in patients with hematologic malignancies. In: Rolston KVI, Rubenstein EB, eds. Textbook of Febrile Neutropenia. 1st ed. Great Britain: Martin Dunitz Ltd. 2001: 111-124.
  12. Gurwith MJ, Brunton JL, Lank BA, Ronald AR, Harding GKM. Granulocytopenia in hospitalized patients. I. Prognostic factors and etiology of fever. Am J Med 1978;64:121-6.
  13. Klastersky J, Zinner SH, Calandra T, Gaya H, Glauser MP, Meunier F, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Can Clin Oncol 1988;24 Suppl 1;35-45.
  14. Rintala E. Incidence and clinical significance of positive blood culture in febrile episodes of patients with hematological malignancies. Scan J Infect Dis 1994;26:77-84.
  15. Rolston KVI. Expanding the options for risk-bases therapy in febrile neutropenia. Diagn Microbiol Infect Dis 1998;31:411-416.
  16. Freifeld AG, Walsh TJ, Pizzo PA. Infections in the cancer patient. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:2659-704.
  17. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. Clinical Infectious Diseases 1993;17(Suppl 2):S378-84.
  18. Rolston KVI. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clinical Infectious Diseases 1999;29:515-21.
  19. Ramphal R, Bolger M, Oblon D, et al. Vancomycin is not an essential component of the initial empiric treatment regimen of febrile neutropenic patients receiving ceftazidime: a randomized comparative study. Antimicrob Agents Chemother 1992;36:1062-7.
  20. Rolston KVI, Elting L, Waquespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996;42:348-353.
  21. Yadegarynia D, Rolston KVI, Tarrand J, Raad II. Current spectrum of bacterial infection in patients with hematological malignancies and solid tumors. Abstracts of the 40th Annual Meeting of Infectious Diseases Society of America (IDSA), Abstract 139, Chicago, Illinois, USA, 2002.
  22. Ramphal R. Is Monotherapy for Febrile Neutropenia Still a Viable Alternative?. Clinical Infectious Diseases 1999;29:508-14.
  23. Del Favero A, Menichetti F, Micozzi A, Bucaneve G, Martino P. Double-Blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactan vs. piperacillin-tazobactan plus amikacin as empiric therapy for febrile neutropenic cancer patients [abstracts no 1092]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999. September 26-29; San Francisco, CA: American Society of Microbiology, 1999:722.
  24. Glasmacher A, Hahn C, Molitor E, Fixson A, Mey U, Sauerbruch T, et al. A randomized comparison of Piperacillin-Tazobactan vs. Ceftriaxone and Gentamicin in 172 severely neutropenic patients with hematologic malignancies [abstracts 1090]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999. September 26-29; San Francisco, CA American Society of Microbiology,1999:721.
  25. Bauduer F, Cousin T, Boulat O, Attal M, Molina L, Rossi JF, et al. A Randomized prospective multicenter trial of cefpirome vs. piperacillin-tazobactam in febrile neutropenia [abstracts no 1089]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999. September 26-29; San Francisco, CA: American Society of Microbiology, 1999:720.
  26. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. Clin Oncol. 2000 Aug;18(16):3038-51.
  27. Paganini H, Gomez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L, Iturres AS, Casimir L, Debbag R. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer. 2003 Apr 1;97(7):1775-80.
  28. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer. 2003 Jul 7;89(1):43-49.
  29. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. 2000 Mar;18(5):1012-9.
  30. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001 Feb 1;32(3):402-12.
  31. De Pauw BE. Treatment of documented and suspected neutropenia-associated invasive fungal infections. J Chemother. 2001 Nov;13 Spec No 1(1):181-92.
  32. Graybill J. The future of antifungal therapy. Clinical Infectious Diseases 1996; 22(Suppl.2): 166-78.
  33. Rolston KV. Fungal infections in immunosuppressed cancer patients. Med Microbiol Lett 1996; 5: 315-318.
  34. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the neutropenic patient--new views of an old problem. Hematology (Am Soc Hematol Educ Program). 2001;:113-39.
  35. Pizzo PA. Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. N Engl J Med 1993;328(18):1323-32.
  36. Joshi P, Hershow R, Vernon M. Risk factors for and outcomes of vancomycin-resistant and susceptible enterococcal bacteremia [abstracts 1716] In: Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999. September 26-29; San Francisco, CA: American Society of Microbiology,1999:642.
  37. Meyer RD, Singer C. Overview of patients with neutropenia: Old and New Treatment Modalities. Clinical Infectious Diseases 1993;17(Suppl 2):S390-1.
  38. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 Oct 15;18(20):3558-85.
Consideraciones generales
Evaluación inicial del paciente con neutropenia febril
Terapia antibiótica empírica
Recomendaciones para tratamiento de pacientes neutropénicos febriles
Infecciones fúngicas y virales
Medidas adicionales
Referencias

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit